Net income · 2020–2025

Rxo net income

−$100M+$190M · FY2025

Rxo (RXO) reported −$100M in net income for fiscal 2025, +$190M from the year before.

$43.0M2020$150M2021$92.0M2022$4.0M2023−$290M2024−$100M2025
Rxo — Net income, 2020–2025
Fiscal yearNet incomeChangeFiling
FY20252025-12-31−$100M+$190MOpen →
FY20242024-12-31−$290M−$294MOpen →
FY20232023-12-31$4.0M−95.7%Open →
FY20222022-12-31$92.0M−38.7%Open →
FY20212021-12-31$150M+248.8%Open →
FY20202020-12-31$43.0M—Open →

Net income — Net income is profit after tax and all expenses, as reported in the annual filing. Companies reporting a loss are excluded from this ranking.

Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026

Net income at companies of similar size

Full ranking by net income →

Cite this page

Ready-made references for the figures on this page, as published on September 25, 2026.

Wikipedia

{{cite web |title=Rxo net income |url=https://companiesranked.com/en/company/rxo/net-income |website=CompaniesRanked |date=2026-09-25 |language=en}}

APA 7

CompaniesRanked. (September 25, 2026). Rxo net income. CompaniesRanked. https://companiesranked.com/en/company/rxo/net-income

BibTeX

@misc{companiesranked-en-company-rxo-net-income-2026,
  author       = {{CompaniesRanked}},
  title        = {{Rxo net income}},
  year         = {2026},
  howpublished = {\url{https://companiesranked.com/en/company/rxo/net-income}},
  note         = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
  urldate      = {2026-09-25}
}

The filing itself

The numbers above are read from this document: 10-K · 0001929561-26-000013 · February 9, 2026

{{cite web |title=Rxo net income — 10-K (0001929561-26-000013) |url=https://www.sec.gov/Archives/edgar/data/1929561/000192956126000013/rxo-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-09}}

The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.

← Rxo overview